Your email has been successfully added to our mailing list.

×
0 0.000463320463320481 0.00177606177606192 0.00239382239382241 0.00378378378378385 0.00772200772200772 0.00841698841698844 0.00795366795366796
Stock impact report

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza [Yahoo! Finance]

AstraZeneca PLC - American Depositary Shares (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
Company Research Source: Yahoo! Finance
approved its RNA-targeted therapy, olezarsen, in adults with familial chylomicronemia syndrome (FCS). The drug will be marketed under the trade name Tryngolza. The FDA's nod to Tryngolza makes it the first approved treatment for FCS in the country. The drug's commercial launch is part of management's broad strategy to deliver a steady flow of wholly-owned medicines to patients. Besides being Ionis' first wholly-owned drug, Tryngolza marks the company's first independent commercial launch, expected before this year's end. The approval is supported by results from the phase III BALANCE study, where FCS patients treated with olezarsen achieved significant triglyceride-lowering and substantial reductions in acute pancreatitis attacks in FCS patients. A regulatory filing for the drug is currently under review by the EMA, also supported by data from this study. FCS is a rare genetic disease marked by extremely elevated triglyceride levels. People living with this condition are at high Show less Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
AZN alerts

from News Quantified
Opt-in for
AZN alerts

from News Quantified